Health Care Select Sector SPDR Fund (XLV)
| Assets | $34.95B |
| Expense Ratio | 0.08% |
| PE Ratio | 21.11 |
| Shares Out | 249.62M |
| Dividend (ttm) | $2.39 |
| Dividend Yield | 1.73% |
| Ex-Dividend Date | Jun 23, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 36.59% |
| Volume | 11,341,580 |
| Open | 139.23 |
| Previous Close | 139.72 |
| Day's Range | 138.10 - 139.81 |
| 52-Week Low | 127.35 |
| 52-Week High | 157.59 |
| Beta | 0.64 |
| Holdings | 62 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
55.96% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 11.75% |
| Johnson & Johnson | JNJ | 8.48% |
| AbbVie Inc. | ABBV | 7.68% |
| UnitedHealth Group Incorporated | UNH | 6.33% |
| Abbott Laboratories | ABT | 4.56% |
| Merck & Co., Inc. | MRK | 4.22% |
| Thermo Fisher Scientific Inc. | TMO | 3.66% |
| Intuitive Surgical, Inc. | ISRG | 3.23% |
| Boston Scientific Corporation | BSX | 3.05% |
| Amgen Inc. | AMGN | 3.00% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
| Mar 18, 2024 | $0.52294 | Mar 21, 2024 |
Performance
XLV had a total return of -9.55% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.20%.
News
2 Call Writing Funds Providing Monthly Distributions For Passive Income
Call writing closed-end funds can offer attractive monthly distributions, along with the opportunity to trade at discounts to their historical net asset values. That discount can create an opportunity...
XLV: Market Overreaction Could Drive Double Digit Shareholder Yield
Healthcare sector trades at a historic discount due to patent expirations, managed care uncertainty, and drug pricing proposals, but pessimism is overdone. Key catalysts include potential M&A activity...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
XLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare?
Healthcare is a defensive sector with strong long-term growth drivers like demographics, innovation, and rising healthcare spending. I rate XLV a buy due to its diversified exposure across healthcare ...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Health care sector is resilient, 'won't stay down forever', says Evan May Wealth's Brooke Evans
Brooke May, Evans May Wealth managing partner, joins 'Closing Bell Overtime' to talk what sectors she is keeping an eye on in this market.
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.
For investors worried about elevated market valuations, they may be just what the doctor ordered.
Gill: We're at a real inflection point for healthcare
Lisa Gill, JP Morgan healthcare analyst, on “Worldwide Exchange,” says healthcare is at an inflection point, with UnitedHealth poised for long-term gains as big investors bet on a turnaround.
Mizuho's Jared Holz on how to play the underperforming health care sector
Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit by the FDA and his read on the healthcare sector.
Final Trades: Netflix, Wynn Resorts, Buckle and the XLV
The Investment Committee give you their top stocks to watch for the second half.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Key ETF Asset Class Performance
The market ended the month of July on a down note, but the S&P 500 still ended the month with a gain of 2.3%. While domestic equities posted small gains in July, there was quite a bit of disparity amo...
Beyond Broad Healthcare: A Smarter Prescription for Growth
Investing in healthcare has long been a cornerstone of defensive, long-term growth strategies. It is, after all, a massive and expanding segment of the global economy.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz
Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense rat...
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
XLV: The S&P 500's Most Discounted Sector? Uncover The Hidden Risk
The healthcare segment, and therefore XLV, is, in terms of relative valuations, the most attractive earning-driven sector. The strong dissonance between earnings expectations and price decline highlig...
2 Healthcare Picks For Distributions And Attractive Valuations
Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benef...
I've never seen a setup this negative for health care job growth, says Bancreek's Pachman
CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.